Protox to present at the 11th Annual Rodman & Renshaw Healthcare Conference

    VANCOUVER, Sept. 9 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader
in the development of receptor targeted fusion proteins, today announced that
Dr. Fahar Merchant, President & CEO of Protox Therapeutics, will present at
the 11th Annual Rodman & Renshaw Healthcare Conference. The conference runs
from Wednesday, September 9 through Friday, September 11 at the Palace Hotel
in New York City. Dr. Merchant's presentation is at 9:10 a.m. ET on Friday,
September 11 in the Garrison Salon on the 5th floor of the hotel and will be
webcast live from Protox's website.
    Dr. Merchant will present the corporate story and upcoming milestone
highlights, including an update on TRIUMPH, a double-blinded placebo
controlled Phase 2b study of PRX302 in patients with benign prostatic
hyperplasia (BPH). Dr. Merchant will also be presenting 12-month data from the
Phase 2a open-label BPH study.

    About Protox

    Protox Therapeutics is a leader in advancing novel, receptor targeted
fusion proteins. Two novel drug candidates derived from the company's
INxin(TM) and PORxin(TM) platforms are being developed in three clinical
programs. Protox's lead program, PRX302 (PORxin), is currently being studied
in a Phase 2b placebo controlled trial to treat benign prostatic hyperplasia
(BPH or enlarged prostate). Positive Phase 2a results treating BPH patients
were released at the end of 2008 and a phase 2a clinical trial evaluating
PRX302 for the treatment of localized prostate cancer is ongoing. A Phase 2a
clinical trial evaluating PRX321 (INxin) for the treatment of primary brain
cancer has been completed and the drug has received Fast Track Designation and
Orphan Drug Status from the US FDA and EMEA. Protox is also collaborating with
the U.S. National Institutes of Health (NIH) on a research program focused on
the discovery of next generation fully human targeted therapeutics.

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information:

For further information: James Beesley, Senior Director, Investor
Relations, Protox Therapeutics, (604) 484-0975,; Michael Moore, Investor Relations, Equicom
Group, (416) 815-0700 x 241,

Organization Profile

Sophiris Bio, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890